PD-1 CAR-T cell as well as preparation method and application thereof

A technology of PD-1CAR-T and PD-1, applied in the field of PD-1CAR-T cells and its preparation, can solve the problems of T cell function exhaustion, T cell death, T cell failure to recognize tumor cells, etc., and achieve high-efficiency tumor The effect of lethal activity
CN106399255AActive Publication Date: 2017-02-15四川阿思科力生物科技有限公司
3 Cites 22 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
四川阿思科力生物科技有限公司
Publication Date
2017-02-15

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a PD-1 CAR-T cell as well as a preparation method and an application thereof. Through a transformation method of modifying the T cell by virtue of a chimeric antigen receptor, PD1CD8TM41BBCD3[zeta] molecules are expressed in the T cell. The CAR-T cell prepared by the method can specifically recognize and bind tumor cells which achieve high-expression in PDL-1 protein; therefore, the CAR-T cell can be applied to the preparation of medicines for preventing and treating tumor diseases.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of cell medicine for tumor treatment, in particular to a PD-1 CAR-T cell and its preparation method and application. Background technique

[0002] With the gradual progress of tumor immunotherapy research, programmed death growth factor-1 (PD-1 / CD 279 ) and its ligand PD-L1 / 2 (B7-H1 / CD274) have been acquired as important members of the tumor microenvironment. favored by many researchers. On September 4, 2014, the U.S. Food and Drug Administration (food and drug adm inistration, FDA ) approved Keytruda (pembrolizum ab ) for the treatment of patients with advanced or unresectable melanoma who have not responded to other drug treatments, becoming an obstacle It is the first FDA-approved drug to block the PD-1 cell pathway. PD-1 was first discovered in 1992, and it is mainly expressed in T cells, regulatory T cells, "exhausted" T cells, B cells, and activated cells. Nuclear cells, dendritic cells, natural killer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More